Glenmark Life Sciences Ltd
NSE:GLS
Operating Margin
Glenmark Life Sciences Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
G
|
Glenmark Life Sciences Ltd
NSE:GLS
|
134.9B INR |
25%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
831.3B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.7B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
214.8B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
190.7B CHF |
32%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
160.2B GBP |
23%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
210.3B USD |
35%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
116.8B EUR |
22%
|
Glenmark Life Sciences Ltd
Glance View
Glenmark Life Sciences Ltd., a spin-off from the parent company Glenmark Pharmaceuticals, has carved out its niche in the competitive world of active pharmaceutical ingredients (APIs). This Mumbai-based entity emerged as an independent public company, growing its presence in both the domestic and international markets. Glenmark Life Sciences strategically focuses on the manufacture and supply of high-quality APIs used across a diverse range of therapeutic areas including cardiovascular, central nervous system disorders, diabetes, pain management, and oncology. By maintaining a robust portfolio of over 120 APIs, the company ensures its penetration in the growing pharmaceutical sector, which increasingly demands reliable and efficient raw materials for drug production. Through its four state-of-the-art manufacturing facilities, Glenmark Life Sciences capitalizes on its well-established research and development capabilities to enhance its manufacturing processes and expand its product range. The company's business model is meticulously designed around long-term relationships with major pharmaceutical players, fostering partnerships that drive consistent revenue streams. By leveraging cost-effective manufacturing practices and an expansive distribution network across major pharmaceutical markets, Glenmark Life Sciences not only optimizes its production capabilities but also ensures timely delivery and high-quality standards. The company's success rests on its ability to balance operational efficiency with strategic expansion into high-growth markets, reinforcing its reputation as a reliable API supplier in the global pharmaceutical industry.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Glenmark Life Sciences Ltd's most recent financial statements, the company has Operating Margin of 25%.
You don't have any saved screeners yet